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Abstract
Introduction: Patients with a history of myocardial infarction (MI) are often at risk for complications, including
subsequent MI and death. Use of prognostic markers may aid in preventing these poor outcomes. Hyperuricemia is
associated with increased risk for coronary heart disease (CHD) and/or mortality; however, it is unknown if serum
urate (sUA) levels predict outcomes in patients with previous MI. The purpose of this study was to assess
hyperuricemia as a biomarker of CHD outcomes in such patients.
Methods: These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1
randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily
aspirin administration over three years in individuals with documented MI. The primary outcome measures were
all-cause death, CHD mortality, coronary incidence, and stroke by quartile of baseline sUA. A sub-analysis of all
outcome measures in the presence or absence of gouty arthritis was also performed.
Results: Of 4,524 enrolled participants, data on 4,352 were analyzed here. All outcomes were greatest for patients
in the fourth sUA quartile. In multivariate regression models, the hazard ratios (HR) for patients in the highest
quartile were 1.88 for all-cause mortality (95% confidence interval (CI), 1.45 to 2.46), 1.99 for CHD mortality (95% CI,
1.49 to 2.66), and 1.36 for coronary incidence (95% CI, 1.08 to 1.70). Participants with untreated gout had an
adjusted hazard ratio ranging from 1.5 to 2.0 (all P < 0.01) for these outcomes. Participants with gout who were
receiving treatment did not exhibit this additional risk.
Conclusions: sUA and untreated gout may be independent prognostic markers for poor all-cause and CHD
mortality in patients with recent acute MI.
Introduction
In 2010, the estimated annual incidence of myocardial
infarction (MI) in the US was 610,000 new attacks and
325,000 recurrent attacks [1]. Following MI, 16% and
22% of men and women, respectively, between the ages
of 40 and 69 years, experience a recurrent MI or fatal
coronary heart disease (CHD) [1]. Since the underlying
pathophysiology of disease in patients with acute coron-
ary syndrome (ACS) varies widely, accurate risk stratifi-
cation to determine appropriate management and
improve outcomes is essential. As such, the use of prog-
nostic biomarkers may facilitate the ability to anticipate
complications following MI and provide timely preven-
tive care to at-risk individuals [2]. For example,
increased concentration of cardiac troponin can predict
adverse events following MI or ACS [3]. Other markers
of post-MI or post-ACS outcomes include N-terminal
pro-B-type natriuretic peptide, inflammatory markers
such as C-reactive protein (CRP), monocyte chemoat-
tractant protein-1, and interleukin-6 [2,4,5].
Hyperuricemia is known to be correlated with a
greater risk for coronary artery calcification, a surrogate
measure of coronary atherosclerosis [6]. Both asympto-
matic hyperuricemia and gout have been identified as
independent risk factors for the development and pro-
gression of cardiovascular disease (CVD), CVD mortal-
ity, and all-cause mortality, in a variety of populations
[7,8]. However, it is unknown whether this excess risk
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extends beyond the initial coronary event. In this study,
we hypothesized that mortality rates increase with
serum urate levels (sUA) in patients with established
CHD. To test this, we analyzed data from a three-year
prospective, observational study that monitored levels of
sUA in patients with histories of MI.
Materials and methods
Study design
This study was performed as a post hoc analysis using
datasets from the Aspirin Myocardial Infarction Study
(AMIS) (ClinicalTrials.gov Identifier: NCT00000491), a
National Heart, Lung and Blood Institute (NHLBI)-
sponsored 1:1 randomized, double-blind clinical trial. It
examined the hypothesis that daily administration of 1 g
of aspirin orally in 2 divided doses to individuals with
documented CHD would result in significantly reduced
mortality over a three-year period [9]. Ethical approval
was obtained at each of the enrolling sites of this study.
All participants provided informed consent.
The design of the AMIS has been described previously
[9]. In brief, 4,524 persons between 30 and 69 years of
age were randomized 8 weeks to 5 years after a qualify-
ing MI to receive either 1 g aspirin per day (n = 2,267)
or placebo (n = 2,257) over a 13-month period at 30
clinical centers starting in 1974. Main inclusion criterion
was presence of documented MI. The main exclusion
criteria included history of aspirin intolerance, severe
peptic ulcer disease, previous cardiovascular (CV) sur-
gery, uncontrolled hypertension, and use of anticoagu-
lants, aspirin, dipyridamole, or sulfinpyrazone. The study
also followed participants for a minimum of three years
for mortality outcomes and non-fatal CHD events. Sub-
committees of investigators adjudicated CV and mortal-
ity outcome assessments in a standardized manner.
Enrollees reported to clinical centers every four months
except the first post-randomization visit that occurred at
the end of month one. Participants were educated about
avoiding aspirin and aspirin-containing over-the-counter
medications; acetaminophen was suggested for analgesic
use. The last study visit in the trial was August 6, 1979,
when all study medications were discontinued and treat-
ment assignment was revealed.
Outcome measures
The present analysis included data from all participants
with information on sUA at baseline (n = 2,169 in the
aspirin group; n = 2,183 in the placebo group; n = 4,352
overall). The analysis also utilized annual follow-up data
from all participants. The outcome definitions were
similar to those of AMIS: 1) all-cause mortality; 2) CHD
mortality, defined as death from definite MI documen-
ted by electrocardiogram and enzyme changes or
autopsy, deaths suspected to be due to MI, and sudden
unexpected deaths (death within one hour of onset of
symptoms, excluding deaths from accidents, homicides,
or suicides); 3) coronary incidence, defined as CHD
mortality or non-fatal MI; and 4) fatal or non-fatal
stroke [9].
Gouty arthritis, defined as a lifetime history of self-
reported physician diagnosis of gout at baseline or any
time during the study was another covariate of interest.
This case definition is often used in epidemiological stu-
dies and has been found to have excellent sensitivity
[10-12]. The specificity may not be high. Nevertheless,
as long as this type of measurement error is non-differ-
ential (that is, the magnitude and direction of error is
the same in all comparison groups) its impact on study
analyses will be negligible. Because participants seldom
had gout flares and/or confirmation by joint aspiration
by the study physician at the time of study visits, case
definition of gouty arthritis included use of gout medi-
cations. Gout medications included allopurinol, probe-
necid, and colchicine (dosage information not available);
sulfinpyrazone use was not permitted in the trial.
Because of these data, outcomes by gout status were
investigated as a secondary analysis in which the partici-
pant group without gout was compared to a) partici-
pants with gout who received treatment, and b)
participants with untreated gout.
Analytical approach
The hypothesis tested for this study was that hyperuri-
cemia and gout are risk factors for CHD and all-cause
mortality among those with existing CAD. All data for
the two study arms were analyzed separately prior to
pooling, as regular aspirin use may have statistical and
biological impacts on sUA concentration, gout and the
study outcomes. Because the distribution of sUA is sys-
temically different between men and women, quartile
cutoffs were defined separately for each, based on base-
line measurements. For the aspirin group, quartile 1 was
defined as 2.5 to 4.5 mg/dL for men, 1.4 to 5.25 mg/dL
for women; quartile 2 was 4.53 to 5.37 mg/dL for men,
5.27 to 6.03 mg/dL for women; quartile 3 was 5.38 to
6.45 mg/dL for men, 6.05 to 7.0 mg/dL for women; and
quartile 4 was 6.47 to 10.45 mg/dL for men, 7.02 to
12.52 mg/dL for women. For the placebo group, quartile
1 was defined as 2.38 to 4.48 mg/dL for men, 1.83 to
5.28 mg/dL for women; quartile 2 was 4.5 to 5.42 mg/
dL for men, 5.3 to 6.03 mg/dL for women; quartile 3
was 5.47 to 6.48 mg/dL for men, 6.05 to 6.97 mg/dL for
women; and quartile 4 was 6.52 to11.05 mg/dL for men,
6.98 to 12.12 mg/dL for women. The corresponding fig-
ures in SI units (μmol/L) can be calculated by multiply-
ing by 59.48. The covariates used in the present analyses
were age, gender, African American ethnicity, body mass
index, blood pressure/hypertension, smoking, diabetes
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status, physical activity measure, hyperlipidemia, hyper-
triglyceridemia, renal function, and other non-steroidal
anti-inflammatory drug use. Participants who were
actively treated for diabetes, hypertension, and hyperlipi-
demia were considered to have those conditions.
Chi-square tests were used to assess statistical signifi-
cance between cumulative incidences of outcomes by
study group. For primary analyses, we used multivariable
Cox regression models to generate hazard ratios (HR)
after ensuring the condition of proportionality was met.
In these regressions, time to the event was modeled as a
function of baseline sUA concentration. Since the life-
time duration of hyperuricemia was unknown, we recog-
nized that the Cox models may be subject to left
censoring and the data were reanalyzed using logistic
regression models. The results of logistic regression




Baseline characteristics of the study group stratified by
quartile of sUA concentration are presented in Table 1.
The population receiving aspirin had a mean age of 54.9
± 8.1 years at randomization, and consisted of 88.5%
men and 6.4% African Americans. Individuals receiving
placebo had a mean age of 54.9 ± 7.9 years, and con-
sisted of 89.6% men and 5.9% African Americans. The
mean age at first and most recent MI was 52.7 years
and 53.2 years, respectively.
Serum uric acid at baseline and cumulative incidence of
outcomes
Quartiles of sUA concentrations were defined following
baseline measurements at randomization (Table 1). The
mean sUA values for the aspirin and placebo groups
were 6.15 ± 1.43 mg/dL (range 1.4 to 12.52 mg/dL) and
6.14 ± 1.35 mg/dL (range 1.83 to 12.02 mg/dL), respec-
tively. Cumulative incidence of each outcome (all-cause
death, CHD mortality, coronary incidence, and stroke)
was highest in the fourth sUA quartile of each study
group (aspirin, placebo, and all study participants; Figure
1). Notably, the cumulative incidence of all-cause death
and CHD mortality was greater by 71% and 83%, respec-
tively, from sUA quartile 1 to quartile 4. In each group,
cumulative incidence of all-cause death, CHD mortality,
and coronary incidence outcomes were statistically sig-
nificantly higher in patients in the fourth quartile than
in the respective first quartile (P < 0.05).
Cox regression models were used to calculate HRs per
quartile of sUA for each outcome. Since there was no
difference between the aspirin and placebo groups in
terms of risk by sUA quartile, these data were subse-
quently pooled. Table 2 provides the estimated relative
risk for each of the study outcomes. Patients in quartile
4 had the highest risk for each outcome, including an
adjusted HR of 1.88 (95% CI, 1.45 to 2.46) for all-cause
death, 1.99 (95% CI, 1.49 to 2.66) for CHD mortality,
1.36 (95% CI, 1.08 to 1.69) for coronary incidence, and
1.31 (95% CI, 0.69 to 2.49) for stroke. When sUA was
analyzed as a continuous variable, each unit increase in
sUA was associated with risk of all-cause death with an
adjusted hazard ratio of 1.23 (1.15 to 1.31, P < 0.001),
CHD mortality with a hazard ratio of 1.24 (1.16 to 1.33,
P < 0.001), and coronary incidence with a hazard ratio
of 1.12 (1.10 to 1.19, P < 0.01); this trend was not statis-
tically significant for stroke (hazard ratio 1.08, 0.91 to
1.29, P = 0.37).
Incidence of study outcomes by gout status
Records of all study participants were utilized for sub-
group analysis of study outcomes by gouty arthritis.
Mean baseline sUA was 6.06 ± 1.33 mg/dL in partici-
pants without gout, 7.18 ± 1.80 mg/dL in participants
with gout and on gout medications, and 7.00 ± 1.66 mg/
dL in participants with gout not receiving gout medica-
tion (P < 0.001 for all gout groups compared with
patients without gout; Table 3).
The cumulative incidence of study endpoints by gout
status is presented in Figure 2. Participants with
untreated gout experienced higher all-cause mortality
(16.9% of study group), CHD mortality (16.9%) and cor-
onary incidence (22.5%), compared to patients without
gout or those who received gout medication.
Table 3 provides the results of secondary analysis on
the relationship between gout medications and out-
comes, as determined by Cox regression analysis. Serum
urate was higher in the gout categories compared to the
non-gout category (P < 0.01). Notably, risk for all study
outcomes in patients treated with gout medications was
indistinguishable from that of patients without gout.
However, those with gout not receiving gout medica-
tions had significantly higher risk for all-cause death
(HR 1.73 (95% CI, 1.03 to 2.91), P < 0.05), CHD mortal-
ity (HR 2.00 (95% CI, 1.18 to 3.36), P < 0.01), and cor-
onary incidence (HR 1.67 (95% CI, 1.07 to 2.62), P <
0.05), compared with patients without evidence of gout.
Discussion
The novelty of this study lies in the selection of the pre-
viously unstudied, yet high-risk, population of patients
with existing coronary artery disease, and in the
observed disparities in the outcomes with respect to
gout treatments. Our observations that the patients with
untreated gout have a significantly increased risk for all-
cause death, CHD mortality, and coronary incidence
and that participants with gout on treatment had risk
comparable to those of participants without gout are
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Table 1 Baseline characteristics of participants in the AMIS Study (Number = 4,352)
Aspirin group Placebo group
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total Quartile 1 Quartile 2 Quartile 3 Quartile 4 Total
sUA range, mg/dL men 2.5-4.5 4.52-5.37 5.38-6.45 6.47-10.45 2.50-10.45 2.38-4.48 4.5-5.42 5.47-6.48 6.52-11.05 2.38-11.05
women 1.4-5.25 5.27-6.03 6.05-7 7.02-12.52 1.40-12.52 1.83-5.28 5.3-6.03 6.05-6.97 6.98-12.12 1.83-12.12
Number 543 541 541 544 2,169 547 539 551 546 2,183





































































































Men, % 88.8 88.2 88.4 88.6 88.5 89.8 89.4 89.7 89.7 89.6
African American, % 5.7 4.3 6.7 9 6.4 7.1 5.9 3.1 7.5 5.9
Physical examination data
Sedentary lifestyle, % 16.7 16.3 17.4 21.3 17.9 16.8 15.6 15.4 20.9 17.2
Alcohol usea, % 88.4 84.7 82.1 82 84.3 88.1 84.6 85.3 80.6 84.7
Smokerb, % 40.7 40.1 31.8 29.6 35.5 39.9 37.3 31.2 32.8 35.3
Heavy smokerc, % 10.1 10.3 12.1 10 10.6 7.2 5.8 15.7 11.4 9.8




































































Table 1 Baseline characteristics of participants in the AMIS Study (Number = 4,352) (Continued)













Triglycerides, mg/dL (SD) 160.7 (130.0) 173.3
(101.6)
190.6 (149.1) 228.7 (192.2) 189.9 (159.2) 153.3
(86.2)
162.7 (97.0) 191.5 (116.6) 230.1 (169.3) 185.2 (125.7)
Comorbidities, %
Number of prior MI
1 88.4 86.7 86.1 84.2 86.4 86.1 88.7 90.0 83.0 86.9
2 10.1 12.4 12.6 13.6 12.2 11.3 10.4 8.5 14.7 11.2
≥ 3 1.5 0.9 1.3 2.2 1.5 2.6 0.9 1.5 2.4 1.8
History of diabetes 13.4 8.1 9.2 8.8 9.9 17 10.4 7.8 10.1 11.3
History of renal impairment 4.2 4.6 5.2 6.6 5.2 3.7 4.3 4.9 6.8 4.9
Gout flaresd 3.1 4.4 4.3 8.3 5.0 3.5 2.2 4.5 7.3 4.4
Medications, %
Gout medicationsd, e 4.2 4.1 3.1 5.0 4.1 3.3 2.0 4.5 4.8 3.7
Non-aspirin NSAIDs 1.5 1.7 0.4 1.8 1.3 0.7 0.9 0.9 1.3 1.0
Anti-diabetic medications 7.9 2.8 3.5 3.3 4.4 8.0 4.8 3.4 5.7 5.5
Blood pressure medications 5.7 8.3 8.9 18.4 10.3 6.4 7.8 8.5 16.7 9.8
Lipid-lowering medications 5.3 5.7 4.6 4.6 5.1 4.9 3.9 5.4 3.8 4.5




















Minimum (years) 1.0 0.9 0.9 0.9 0.9 0.90 0.90 0.8 0.9 0.8
Maximum (years) 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.1 3.2
a < 1.5 oz/day; bIncludes cigarettes, pipes, and cigars; c > 45 cigarettes/day; dGout flares and medications determined at baseline; eIncludes probenecid, allopurinol, and colchicine; fFollow up from baseline to last
















important, yet must not be over-interpreted, given the
modest sample size. As previously mentioned, the asso-
ciation between gout and the risk for CV outcomes is
well recognized. The results reported here provide yet
another reason for improving the treatment of gout
[13,14].
Findings from this present study support the potential
use of sUA as a biomarker for mortality outcomes in
adult patients with pre-existing MI. Among participants
of the AMIS Study, there is an association between sUA
and risk of all-cause death, CHD mortality, and coron-
ary incidence in individuals with a history of MI. Similar
results were reported in a recent Israeli study, where,
among 2,966 patients with documented CHD followed
for 6.2 years, including those with a history of MI in the




































Figure 1 Cumulative incidence of study endpoints according to baseline sUA concentration for patients receiving aspirin, placebo
group, and all study participants: follow-up analysis of 4,352 participants in the AMIS Study. Aspirin group: quartile 1-2.5 to 4.5 mg/dL
for men, 1.4 to 5.25 mg/dL for women; quartile 2-4.53 to 5.37 mg/dL for men, 5.27 to 6.03 mg/dL for women; quartile 3-5.38 to 6.45 mg/dL for
men, 6.05 to 7.0 mg/dL for women; quartile 4-6.47 to 10.45 mg/dL for men, 7.02 to 12.52 mg/dL for women. Placebo group: quartile 1-2.38 to
4.48 mg/dL for men, 1.83 to 5.28 mg/dL for women; quartile 2-4.5 to 5.42 mg/dL for men, 5.3 to 6.03 mg/dL for women; quartile 3-5.47 to 6.48
mg/dL for men, 6.05 to 6.97 mg/dL for women; quartile 4-6.52 to 11.05 mg/dL for men, 6.98 to 12.12 mg/dL for women. For all outcomes
except stroke, the difference in incidence between the first and fourth quartiles and a linear trend test were statistically significant (P < 0.05).
AMIS, Aspirin Myocardial Infarction Study; CHD, Coronary Heart Disease, sUA, serum urate.
Table 2 Multivariable adjusted hazard ratio for each of
the study outcomes stratified by quartile of serum uric
acid concentration
Hazard ratio (95% CI)
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Outcome N = 1,090 N = 1,080 N = 1,092 N = 1,090
























aP < 0.001 in comparison to the first quartile; bP < 0.01. in comparison to first
quartile; cTrend test performed using serum urate as a continuous variable.
The covariates adjusted for in this regression included: age, gender, African-
American ethnicity, body mass index, blood pressure/hypertension, smoking,
diabetes status, physical activity measure, hyperlipidemia,
hypertriglyceridemia, renal function, and other non-steroidal anti-inflammatory
drug use.
CHD, coronary heart disease; CI, confidence interval; N, number.
Table 3 Multivariable adjusted hazard ratio for each
study outcome by gout status
Hazard Ratio (95% Confidence Interval)
All study participants
Gout status No gout Treated gout Untreated gout
N = 3,987 N = 129 N = 89
Mean sUA (SD) 6.06 (1.33) 7.18 (1.80) 7.00 (1.66)
All-cause death 1.00 0.84 (0.47, 1.50) 1.73a (1.03, 2.91)
CHD mortality 1.00 0.82 (0.43, 1.54) 2.00b (1.18, 3.36)
Coronary incidence 1.00 0.86 (0.58, 1.34) 1.67a (1.07, 2.62)
Stroke 1.00 2.11 (0.74, 6.03) 0.83 (0.11, 6.04)
aP < 0.05 for comparison of untreated gout group to no gout group; bP < 0.01
for comparison of untreated gout group to no-gout group. The covariates
adjusted for in this regression included: age, gender, blood pressure/
hypertension, smoking, diabetes status, physical activity measure,
hyperlipidemia, hypertriglyceridemia, renal function, and other non-steroidal
anti-inflammatory drug use. Gout medications accounted for in this study
were allopurinol, probenecid, and colchicine. CHD, coronary heart disease;
sUA, serum urate.
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6 months to 5 years prior to enrollment, there was a
significant and positive correlation between the occur-
rence of fatal MI, nonfatal MI, or sudden cardiac death
and increasing baseline sUA (P = 0.0009) [15]. These
results also corroborate the results of the study by Ioa-
chimescu et al. in which post-MI risk for poor outcomes
was predicted by sUA [16].
Among patients with a history of heart failure (HF), a
history of gout increased the risk of readmission due to
HF or death by 63%, and recent acute gout (within 60
days) doubled the risk for HF readmission or death and
increased the risk for all-cause mortality by 76%, after
adjusting for confounders [17]. Of interest, we observed
no association between sUA/gout and stroke outcomes,
which is inconsistent with previous studies [18,19]. It is
uncertain if this is due to the relatively small number of
stroke events that occurred during the AMIS study [20].
At low doses (less than 1 g per day), aspirin reduces
urate excretion in the kidney [21]. At the higher doses
used in this study, aspirin is known to be uricosuric
[22]. Since the two arms of the AMIS were systemati-
cally different all our initial analyses were done sepa-
rately for each and the results were pooled only when
the findings were comparable.
The causal relationship between uric acid, gout, and
the pathogenesis of CHD is under investigation. A grow-
ing body of literature, comprehensively reviewed else-
where [23], points toward the role of uric acid in
promoting atherosclerosis through increased oxidative
stress and inflammation in both gouty and asympto-
matic hyperuricemic patients. In vitro studies have
demonstrated that soluble uric acid promotes inflamma-
tion [24], generates intermediate reactive oxidative spe-
cies [25] and leads to endothelial dysfunction and
proliferation [26]. The presence of the urate transporter,
URAT1, in human vascular smooth muscle cells [27]
provides another link between uric acid and endothelial
dysfunction, but studies are needed to determine if this
and other polymorphisms responsible for hyperuricemia
and gout are also linked to CHD. Several studies have
Figure 2 Cumulative incidence of study endpoints by gout status. For all outcomes except stroke, the rates among gout patients not on
medication were significantly higher than for those without gout. Participants were considered to be treated for gout if they reported use of
allopurinol, probenecid, or colchicine during the study. CHD: Coronary Heart Disease.
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suggested a pathogenic role for uric acid in hypertension
and increased platelet adhesiveness and lysis [28]. Uric
acid has been shown to promote oxygenation of low-
density lipoprotein (LDL) cholesterol, and gout patients
have significantly higher levels of oxidized LDL [23].
While the above evidence suggests a direct role for
uric acid in the progression of CVD, other data suggest
that the oxidative stress may be due to the activity of
xanthine oxidase (XO), of which sUA is a marker. Urate
lowering therapy (ULT) with allopurinol reduced the
level of oxidized LDL in gout patients, while treatment
with benzbromarone did not [29]. In patients with mild
to moderate HF (mean sUA 7.12 mg/dL), allopurinol
improved vascular blood flow (endothelium-dependent
vasodilation) in a steep dose-dependent manner, while
probenecid did not have this effect [30]. Three months
of allopurinol treatment in hyperuricemic patients led to
improvements in endothelial function directly related to
the extent of sUA reduction, and this improvement was
not seen in normouricemic controls treated with allo-
purinol [30]. In mice with experimental MI, treatment
with allopurinol slowed down subsequent left ventricular
remodeling (dilation, hypertrophy, and interstitial fibro-
sis), resulting in substantially improved left ventricular
function. This effect was attributed to the inhibition of
XO in the myocardium, leading to reduced oxidative
stress [31]. Other studies have demonstrated improved
CV outcomes when allopurinol was used in patients
with documented CHD undergoing various interven-
tions [32-34]. These data support the hypothesis that
the oxidative species generated by XO activity contri-
bute to the progression of CVD. However, recent work
in newly hypertensive adolescents has demonstrated the
beneficial effects of ULT with allopurinol [35]. It may be
that both uric acid and XO are involved in the etiology
of CVD through independent and common pathways.
Regardless, since sUA is a direct reflection of XO activ-
ity, it serves as a useful biomarker for CVD risk.
Important caveats are due. First, the results on gout
treatment and improved cardiovascular outcomes should
be treated as hypothesis generating and not causative,
since channeling bias (that is, getting treatment for gout
might be a marker for healthier/health conscious indivi-
duals who may have better outcomes) can make it
impossible to assess the true impact of ULT. Another
piece of evidence suggesting a non-random ‘allocation’
of therapy might be the serum urate concentrations.
The fact that serum urate concentration is not lower in
the treated group suggests that these individuals had
higher serum urate/more severe gout to begin with.
With such a bias, the mortality benefit associated with
urate lowering might be an underestimate. Another
data-related issue is our inability to exclude colchicine
from urate lowering therapies. Our study examined risk
factors for coronary events among those who survived
such an event in the past. The influence of survivor
effect and the importance of lifestyle modification fol-
lowing a diagnosis of coronary artery disease is difficulty
to model in our study. Another important facet of this
study is that it was performed in the 1970s, before the
advent of current sophisticated diagnostic tools to detect
subtle coronary syndromes. The patients with MI
included in the trial are likely to be survivors from a
more definitive, more severe, acute myocardial infarc-
tion. In that context there is a survival bias in that these
individuals are likely to be hardier than those who sur-
vive a non-ST-elevation acute myocardial infarction.
Nevertheless, the outcome we studied, mortality, was
applied uniformly across all strata of urate levels as well
as gout status, and arguably there were no differential
biases.
Other factors can be expected to attenuate the rela-
tionship between hyperuricemia and gout and coronary
events. When multiple risk factors contribute to the risk
of an outcome, the risk factors for the recurrence of the
event tend to be correlated with each other leading to
index event bias. This bias could have resulted in the
underestimation of the true relationship between hyper-
uricemia and gout and coronary events in our study.
Our study data did not have the granularity or statistical
power to discern any differences by the type of gout
medication used. Finally, the effect of residual confound-
ing by unobserved and unadjusted risk factors could not
be estimated in our study.
Conclusions
The data presented here suggest that hyperuricemia is
an independent predictor of all-cause and CHD mortal-
ity, as well as coronary incidence, in individuals with
confirmed CHD. Analysis of sUA levels in patients fol-
lowing MI may be a reliable and inexpensive method for
distinguishing patients at risk for mortality. Measure-
ment of sUA levels may contribute to existing strategies
that stratify risk for secondary CHD events, including
mortality, in patients with previous MI.
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